{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33385574",
  "DateCompleted": {
    "Year": "2021",
    "Month": "04",
    "Day": "01"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "12",
        "Day": "29"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.drudis.2020.12.010",
      "S1359-6446(20)30528-6"
    ],
    "Journal": {
      "ISSN": "1878-5832",
      "JournalIssue": {
        "Volume": "26",
        "Issue": "3",
        "PubDate": {
          "Year": "2021",
          "Month": "Mar"
        }
      },
      "Title": "Drug discovery today",
      "ISOAbbreviation": "Drug Discov Today"
    },
    "ArticleTitle": "Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions.",
    "Pagination": {
      "StartPage": "631",
      "EndPage": "636",
      "MedlinePgn": "631-636"
    },
    "Abstract": {
      "AbstractText": [
        "The Coronavirus 2019 (COVID-19) pandemic represents the greatest worldwide public health crisis of recent times. The lack of proven effective therapies means that COVID-19 rages relatively unchecked. Current anti-COVID-19 pharmacotherapies are drugs originally designed for other diseases, and administered orally or intravascularly. Thus, they can have various adverse effects. A specific anti-Coronavirus drug should not only target the virus per se, but also treat the related respiratory and cardiovascular symptoms. Here, we examine the advantages and disadvantages of current anti-COVID-19 pharmacotherapies, and analyze the reasons why in the era of big data we have not yet established specific coronavirus therapies and related technical bottlenecks. Finally, we present our design of a novel nebulized S-nitrosocaptopril that is under development for targeting both coronaviruses and their related symptoms."
      ],
      "CopyrightInformation": "Copyright \u00a9 2021 Elsevier Ltd. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Cancer Metastasis Alert and Prevention Center, College of Chemistry, Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, Fuzhou University, Fuzhou, Fujian 350116, China; Institute of Oceanography, Minjiang University, Fuzhou, Fujian 350108, China."
          }
        ],
        "LastName": "Lin",
        "ForeName": "Min",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, Fujian Medical University, Fuzhou, Fujian 350108, China."
          }
        ],
        "LastName": "Dong",
        "ForeName": "Hai-Yan",
        "Initials": "HY"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Oceanography, Minjiang University, Fuzhou, Fujian 350108, China."
          }
        ],
        "LastName": "Xie",
        "ForeName": "Huan-Zhang",
        "Initials": "HZ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Cancer Metastasis Alert and Prevention Center, College of Chemistry, Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, Fuzhou University, Fuzhou, Fujian 350116, China; Institute of Oceanography, Minjiang University, Fuzhou, Fujian 350108, China."
          }
        ],
        "LastName": "Li",
        "ForeName": "Yu-Mei",
        "Initials": "YM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Oceanography, Minjiang University, Fuzhou, Fujian 350108, China. Electronic address: cmapcjia1234@163.com."
          }
        ],
        "LastName": "Jia",
        "ForeName": "Lee",
        "Initials": "L"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Drug Discov Today",
    "NlmUniqueID": "9604391",
    "ISSNLinking": "1359-6446"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Angiotensin-Converting Enzyme Inhibitors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Pharmaceutical Preparations"
    },
    {
      "RegistryNumber": "122130-63-6",
      "NameOfSubstance": "S-nitrosocaptopril"
    },
    {
      "RegistryNumber": "9G64RSX1XD",
      "NameOfSubstance": "Captopril"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Angiotensin-Converting Enzyme Inhibitors"
    },
    {
      "QualifierName": [
        "classification",
        "pharmacology"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "epidemiology",
        "physiopathology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "analogs & derivatives",
        "pharmacology"
      ],
      "DescriptorName": "Captopril"
    },
    {
      "QualifierName": [
        "drug effects",
        "metabolism"
      ],
      "DescriptorName": "Cardiovascular System"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Drug Development"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Drug Repositioning"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Nebulizers and Vaporizers"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pharmaceutical Preparations"
    },
    {
      "QualifierName": [
        "diagnostic imaging",
        "metabolism"
      ],
      "DescriptorName": "Respiratory System"
    },
    {
      "QualifierName": [
        "drug effects",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ]
}